Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Prelude Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 128

Market Cap: $299.3M

Website

Clinical Trials

A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

Phase 1

Completed

Conditions: Relapsed/Refractory Mantle Cell Lymphoma
Relapsed/Refractory Acute Myeloid Leukemia
Relapsed/Refractory Myelodysplasia
Relapsed/Refractory Myelofibrosis
Adenoid Cystic Carcinoma
Refractory Chronic Myelomonocytic Leukemia
Relapsed/Refractory Advanced Solid Tumors
Relapsed/Refractory Diffuse Large B-cell Lymphoma

Interventions: Drug: PRT543

First Posted Date: 2019-03-22

Last Posted Date: 2023-03-28

Lead Sponsor: Prelude Therapeutics

Target Recruit Count: 232

Registration Number: NCT03886831

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
UCSF Precision Cancer Medicine Building, San Francisco, California, United States
🇺🇸
Christiana Care Health Services, Christiana Hospital, Newark, Delaware, United States

and more 20 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy